A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Trial Details

NCT ID

NCT06732323

Phase

PHASE3

Sponsor

Qilu Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• ESG401
• Investigator's Choice Chemotherapy

Locations (sample)

• Beijing, China|39.9075,116.39723

Key Eligibility Criteria

• Males or females aged ≥ 18 years ;
• Histologically and/or cytologically confirmed TNBC;
• De novo metastatic or relapsed ≥ 6 months post completion of treatment with curative intent;
• No prior systemic anti-cancer therapy for unresectable recurrent or metastatic disease;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.